Latest research on Betaseron

Human interferon beta (165 residues), cysteine 17 is substituted with serine. Produced in E. coli, no carbohydrates, MW=18.5kD

Latest findings

The first approved DMT for MS, subcutaneous interferon beta-1b (IFNβ-1b, marketed as Betaseron in the USA and as Betaferon in Europe), was approved by the US Food and Drug Administration (FDA) for RRMS in 1993. [source, 2009]
Since the early 1990s, six IMAs have been approved by the US Federal Drug Administration (FDA) for use in MS therapy: interferon-1b, (Betaseron) in 1993, interferon-1a (Avonex) and glatiramer acetate (GA, Copaxone) in 1996, interferon-1a (Rebif) in 2002, Mitoxantrone (Novantrone) in 2000 and Tysabri (Natalizumab) in 2006. [source, 2007]
Of the FDA-approved agents for MS, use of Avonex appeared to exhibit a downward trend (27% in 1998 to 11% in 2000), whereas that of Copaxone and Betaseron appeared to show an upward trend. [source, 2007]
Internists and family medicine practitioners prescribed 12% and 11% of Avonex but negligible numbers for Betaseron and Copaxone. [source, 2007]
A link between depression and IFN-β treatment of MS patients was suggested based on data from the pivotal IFN-β-1b (Betaseron) study in 372 subjects over 5 years, during which five patients (2%), all on active treatment, attempted suicide. [source, 2007]
Interferon beta-1a (Rebif), interferon beta-1b (Betaseron), and glatiramer acetate may all be self-administered subcutaneously but this requires medical guidance initially. [source, 2006]